Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cebranopadol versus morphine prolonged-release for chronic cancer pain
NL-OMON41472Phase 3Withdrawn
- Sponsor
- Grünenthal GmbH
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Chronic cancer pain comparing Cebranopadol with Morphine sulfate prolonged-release (2 arms). Primary endpoint: Average daily rescue medication intake over the last 2 weeks of the Maintenance Phase. Planned start Jul 2013; status: withdrawn.
02
Drugs
cebranopadolmorphine
03
Conditions
Chronic cancer pain
Beyond the preview
Go deeper on NL-OMON41472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41472.